b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Process" Owner="NLM">\n        <PMID Version="1">31332100</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>03</Month>\n            <Day>30</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1549-490X</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>24</Volume>\n                    <Issue>12</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>12</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>The oncologist</Title>\n                <ISOAbbreviation>Oncologist</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Meta-Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>e1315-e1320</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1634/theoncologist.2018-0675</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND">Most guidelines still recommend active surveillance for patients with asymptomatic, unresectable neuroendocrine tumors (NETs). However, recent findings from several randomized placebo-controlled trials suggest that most patients would benefit from active treatment. We conducted a meta-analysis of pooled outcomes from clinical trials in which an active treatment arm was compared with placebo to determine whether active treatment provides a survival advantage.</AbstractText>\n                <AbstractText Label="MATERIALS AND METHODS">This meta-analysis evaluated six trials that compared a medication with placebo in patients with an asymptomatic, metastatic NET. The trials were heterogenous with regard to the active medication (octreotide, lanreotide, sunitinib, everolimus, Lu-Dotatate) and tumor localizations (gastrointestinal, pancreas, lung). Overall survival (OS) and progression-free survival (PFS) for the placebo and active treatment arms were obtained from individual trial data and combined to obtain pooled outcomes.</AbstractText>\n                <AbstractText Label="RESULTS">The individual trials all reported significantly better PFS outcomes for active treatment. The pooled data confirmed this advantage. At months 3, 6, 12, 18, and 24, pooled PFS rates for the placebo and treatment arms, respectively, were 92.9% versus 96.9%; 54.3% versus 83.7%; 35.5% versus 68.5%; 25.1% versus 54.7%; and 17.7% versus 61.0%. OS was also higher in the active treatment groups. At months 6, 12, 24, 36, 48, and 60, OS rates (placebo vs. active treatment), respectively, were 88.1% versus 93.4%; 84.1% versus 86.2%; 67.4% versus 76%; 56.6% versus 64.4%; 49.9% versus 61.0%; and 41.7% versus 45.9%.</AbstractText>\n                <AbstractText Label="CONCLUSION">This meta-analysis confirms findings from recent clinical trials indicating that active treatment yields better survival outcomes than placebo. Importantly, these findings were obtained across a wide range of patient profiles and diverse medical treatments for metastatic NETs. Given the lack of reliable prognostic factors to determine a priori which patients are unlikely to benefit from active treatment, these findings support early treatment in most patients.</AbstractText>\n                <AbstractText Label="IMPLICATIONS FOR PRACTICE">Although most guidelines still recommend active surveillance for patients diagnosed with metastatic neuroendocrine tumors, the results of this meta-analysis, together with recent data from key clinical trials, suggest that most patients could benefit from upfront active treatment. However, more data are needed to confirm this.</AbstractText>\n                <CopyrightInformation>\xc2\xa9 AlphaMed Press 2019.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Capdevila</LastName>\n                    <ForeName>Jaume</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medical Oncology, Vall d\'Hebron University Hospital, Vall d\'Hebron Institute of Oncology, Barcelona, Spain jacapdevila@vhebron.net.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hernando</LastName>\n                    <ForeName>Jorge</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medical Oncology, Vall d\'Hebron University Hospital, Vall d\'Hebron Institute of Oncology, Barcelona, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Perez-Hoyos</LastName>\n                    <ForeName>Santiago</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Biostatistics and Bioinformatics Unit, Vall d\'Hebron Research Institute, Barcelona, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Roman-Gonzalez</LastName>\n                    <ForeName>Alejandro</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Endocrinology, San Vicente Fundacion University Hospital-Antioquia University, Medellin, Colombia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Grande</LastName>\n                    <ForeName>Enrique</ForeName>\n                    <Initials>E</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medical Oncology, MD Anderson Cancer Center, Madrid, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>07</Month>\n                <Day>22</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Oncologist</MedlineTA>\n            <NlmUniqueID>9607837</NlmUniqueID>\n            <ISSNLinking>1083-7159</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Meta\xe2\x80\x90analysis</Keyword>\n            <Keyword MajorTopicYN="Y">Neuroendocrine tumors</Keyword>\n            <Keyword MajorTopicYN="Y">Peptide receptor radionuclide therapy</Keyword>\n            <Keyword MajorTopicYN="Y">Placebo</Keyword>\n            <Keyword MajorTopicYN="Y">Somatostatin analogues</Keyword>\n            <Keyword MajorTopicYN="Y">Targeted agents</Keyword>\n        </KeywordList>\n        <CoiStatement>Disclosures of potential conflicts of interest may be found at the end of this article.</CoiStatement>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>10</Month>\n                <Day>09</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>06</Month>\n                <Day>06</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>25</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>25</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>24</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31332100</ArticleId>\n            <ArticleId IdType="pii">theoncologist.2018-0675</ArticleId>\n            <ArticleId IdType="doi">10.1634/theoncologist.2018-0675</ArticleId>\n            <ArticleId IdType="pmc">PMC6975960</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Lancet. 2016 Mar 5;387(10022):968-977</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26703889</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2011 Feb 10;364(6):501-13</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21306237</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Neuroendocrinology. 2017;104(1):26-32</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26731483</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2011 Feb 10;364(6):514-23</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21306238</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ann Oncol. 2017 Feb 1;28(2):339-343</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27836885</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2016 Nov 10;34(32):3906-3913</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27621394</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>World J Clin Oncol. 2017 Apr 10;8(2):96-99</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28439490</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Contemp Oncol (Pozn). 2017;21(2):115-122</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28947880</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Contemp Oncol (Pozn). 2015;19(5):345-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26793016</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2017 Jan 12;376(2):125-135</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28076709</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Oncologist. 2017 Feb;22(2):165-172</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28179574</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>CMAJ. 2017 Mar 13;189(10):E398-E404</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28385820</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Endocr Relat Cancer. 2017 Feb;24(2):L13-L16</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27965278</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Pancreas. 2017 Jul;46(6):707-714</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28609356</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Aliment Pharmacol Ther. 2011 Jul;34(2):235-42</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21585408</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Crit Rev Oncol Hematol. 2016 Feb;98:122-36</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26597016</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Control Clin Trials. 1986 Sep;7(3):177-88</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">3802833</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Endocrinol Invest. 2017 Nov;40(11):1265-1269</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28550464</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Oncotarget. 2017 Jul 11;8(28):46624-46634</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28402955</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2011 Jul 10;29(20):2835-6</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21632510</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2014 Oct 16;371(16):1556-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25317881</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Neuroendocrinology. 2016;103(2):172-85</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26731013</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>HPB (Oxford). 2017 Apr;19(4):310-320</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28254159</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ecancermedicalscience. 2017 Jan 26;11:716</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28194228</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2011 Jun 10;29(17):2372-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21555696</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Res Synth Methods. 2012 Dec;3(4):257-68</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26053420</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2009 Oct 1;27(28):4656-63</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19704057</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'